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Data on baseline characteristics of children with asthma to predict individual treatment responses are lacking. We
aimed to set up a data-collection system which can easily fill this gap in clinical practice.
A web-based application was developed, named 'Portal for children with respiratory and allergic symptoms',
hereafter called Electronic Portal (EP). It contains health- and disease-related questionnaires on respiratory- and
allergic diseases. All patients, 1–18 years of age, with respiratory- and/or allergic complaints are invited to enter the
EP before their first visit. By using the EP large amounts of data, gathered during routine patient care can be used
for research purposes. This may help to further investigate the different treatment related asthma phenotypes and
will be helpful to monitor risk factors for other atopic diseases and respiratory infections.
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Asthma is the most prevalent chronic illness in child-
hood [1]. The prevalence of asthma is ranging from 4 to
12 percent of school age children [2]. A recent study in
The Netherlands showed that in a population of 1614
school age children 5% had physician-diagnosed asthma,
while an additional 8% had asthma symptoms without
knowing to have asthma [3]. Despite advances in the
management of asthma in children, it continues to be a
condition that has significant impact on children and
their families. In a Dutch study both children with diag-
nosed and undiagnosed asthma had impaired quality of
life scores compared to healthy peers and had higher
rates of absence from school [4]. The AIRE (Asthma
Insight and Reality) study showed only partial effec-
tiveness of asthma care in daily life [5]. In addition,
Fuhlbrigge et al. showed that goals of therapy in asthma,
based on the National Asthma Education and Prevention
Program guidelines, have not been achieved for the* Correspondence: k.zomer-kooijker@umcutrecht.nl
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distribution, and reproduction in any mediummajority of children, although more than 70% had mild
intermittent disease [6]. The impact of asthma on daily
activities is substantial; avoiding exertion (47%) and stay-
ing inside (37%) are common approaches to avoid
asthma symptoms. These data indicate poor control of
asthma in school-age children in affluent countries.
To improve patient care in clinical practice there is an
urgent need for predictors of asthma treatment responses.
Scarce data are available on predictors of treatment re-
sponse. Several studies addressed the predictive capacity
of family history, clinical symptoms, or lung function
parameters for the effect of different treatment regimens.
For example, a parental history of asthma or increased
levels of exhaled Nitric Oxide (eNO) might predict a
beneficial effect of ICS [7-10] while in adults LTRAs might
be especially beneficial in asthma patients who smoke
[11]. In cases where group-wise differences between differ-
ent therapies are lacking [12,13], predictive baseline char-
acteristics might be helpful to predict which therapy has
the best risk-benefit ratio in the individual child.
The evaluation of the predictive capacity of comprehen-
sive clinical and laboratory parameters for treatment
responses requires analysis of a large and diverse patient
population from different clinical settings and prospectiveCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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study in The Netherlands to compare different treatment
strategies for children with respiratory and allergic symp-
toms and to evaluate predictors of treatment responses. In
a strongly internet-supported network of academic and
general pediatricians in The Netherlands (the ‘Expert
Network’) large numbers of patients are recruited and
evaluated using an Electronic Portal. Here we aim to de-




The Electronic Portal (EP) is used by the members of
the Expert Network (EN) as a clinical tool to prospect-
ively collect data in children with respiratory and allergic
symptoms. The EP is used firstly to thoroughly screen






Figure 1 The Dutch Expert Network. 1 = Utrecht, 2 = Nieuwegein, 3 = B
Arnhem, 9 = Deventer, 10 = Ede, 11 = Apeldoorn, 12 = Tilburg, 13 = Enschpossible risk factors, before their first outpatient depart-
ment-visit. Secondly, patients can be followed-up on a
regular basis without intervention of their caregivers. At
start uniform information about atopic diseases, respira-
tory infections, exposure to potential toxins, and
demographic information is collected by the patients.
Afterwards data on treatment, disease control and treat-
ment effects are monitored. In this way pre-treatment
patient characteristics can be related to treatment and
disease outcomes. Recruitment and follow up of children
started in June 2011.
The expert network
In a nationwide collaborative network of Dutch care-
givers at least 3000 children presenting with asthma
symptoms will be included from June 2011. The EN
consists of caregivers in the primary-, second- and third










laricum, 4 = Oss, 5 = Amersfoort, 6 = Veldhoven, 7 = Utrecht, 8 =
ede, 14 = Woerden, 15 = Harderwijk, 16 = Helmond, 17 = Eindhoven.
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in pulmonology, allergology, dermatology, infectiology
and otolaryngology. We aim to include at least 15 large
pediatric clinics (for current status see Figure 1).
Members of the EN are personally instructed how
to use the EP. The EN has three-monthly meetings in
which data from the EP are analyzed and compared
between centers. Information about meetings, diag-
nostic and treatment protocols, and scientific updates
on atopic diseases can be found on a supporting
website.
Children between the ages of 0–18 years, referred to a
member of the EN because of respiratory- or atopic
complaints are eligible to participate and are asked to
participate in the EP. Also known patients are eligible to
participate in the EP. Each centre has its own account.
With this, access is given to the data of their own
patients, and records can be made and printed with
results per patients. Patients with congenital pulmonary
defects or cystic fibrosis are excluded. Also (parents of )
patients who do not understand the Dutch language will
be excluded, however, if children above the age of 11 do
understand the Dutch language well, they are eligible to
participate themselves. Informed consent for use of the
questionnaires and clinical information is given by an
electronic check mark. The medical ethics committee of
the University Medical Centre Utrecht has approved the
protocol.
The electronic portal
The Electronic Portal is a web-based application devel-
oped by the University Medical Centre Utrecht, in col-
laboration with Vital Health software. The EP can be
approached via the url http://www.luchtwegportaal.com.
The supporting website presents information on three
levels: for the patient, the parents, and the members of
the Expert Network, and contains disease information,
information on the EP, and protocols for physicians.
From this website the EP can be entered with a unique
personal code. The information in the EP consists of
personal patient information, validated questionnaires,
diagnostic test results, and an automatic follow up func-
tion. Individual data in the EP are accessible for both the
patient and his caregiver and structured reports can be
generated on screen and on paper. The content of the
EP is summarized in Table 1. Three age-dependent ques-
tionnaire sets are available in the EP, and are automatic-
ally selected based on the age of the child; a set for
children 0–1 years, one for children between 1–11 years
and a set for children above 12, in which most of the
questions are directed to the child itself. The structure
of the EP, and the following order in which the EP is
used is shown in Figure 2.Baseline examination
Screening questionnaires
After entering the EP, parents are asked to fill in screen-
ing questionnaires which aim to screen on the presence
of atopic diseases. Core questions of the ISAAC ques-
tionnaire on asthma, allergic rhinoconjunctivitis and ec-
zema are used for this purpose. In addition, questions
about respiratory infections and food allergy are
included. Based on the answers in the screening part,
additional specific questionnaires on each disease topic
are selected or not, to be filled in subsequently. Informa-
tion about growth parameters, breast feeding and vac-
cination status are obtained from personal health care
files by the parents. This health care file is a document
that every child in the Netherlands owns and is used in
the primary care setting during the first years of live.
The general health status is determined based on the
RAND questionnaire (Table 2). The screening question-
naires also contain questions about known risk factors
for infections (as use of a consoler, day care) and atopic
diseases (as smoking, pets, and breastfeeding).
Additional questionnaires
The aim of the additional questionnaires is to exten-
sively explore the complaints of the patient, his medi-
cation use and habits, and measure the disease
related quality of life. Details of the supplementary
questionnaires in the EP, and the meaning of the cor-
responding scores are given in Table 2. Question-
naires about asthma, respiratory tract infections,
allergic rhinoconjunctivitis, eczema and food allergy
are included. In addition to the questionnaires men-
tioned in Table 2, additional questions about asthma
and rhinoconjunctivitis are included [31]. Besides dis-
ease specific questionnaires, information on environ-
mental factors, pet exposure, (parental) smoking and
social economic status are obtained, partially adopted
from the ISAAC questionnaire [32].
Diagnostic tests
Caregivers from the EN can add results of diagnostic
tests to the EP. Protocols are written to ascertain uni-
form performance of different tests.
Respiratory function
In all new patients suspected for asthma, lung func-
tion and allergy tests are performed according to the
Dutch national guidelines [33]. Spirometric assess-
ments, e.g. maximal flow-volume curves, are mea-
sured according to the ATS/ERS standards [34]. The
highest values of three correctly performed man-
oeuvres are used for analysis. Recorded parameters
are FEV1 (Forced Expiratory Volume in one second)
and FVC (Forced Vital Capacity). To measure the
Table 1 Content of the Electronic Portal for children with respiratory and allergic symptoms
1. Screening Part Includes
Personal data DOB, weight at birth, development, vaccination status
General Health Status RAND questionnaire
General medical history questions Known risk factors for atopic diseases
Screening questions on atopic and infectious diseases ISAAC core questions and non-validated questions
2. Additional Part
Asthma
Symptoms ISAAC additional questions, ACT, medication use
Treatment compliance MARS
Quality of life PAQoL
Infections
Symptoms Non-validated questionnaire
Quality of life OM-6
Allergic Rhinoconjunctivitis
Symptoms ISAAC additional questions, ARIA, medication use
Quality of life RQLQ
Food allergy
Symptoms Non-validated questionnaire
Quality of life FaQoL
Eczema
Symptoms SA-EASI
Quality of life IDQL or CDLQI
3. Diagnostic test results
Lung function tests FEV1, NO, BDR or Methacholine challenge test
Laboratory results Inhalation screening (sIgE)




Treatment compliance MARS scale
Lung function FEV1, NO, BDR or Methacholine challenge test
DOB = Date of Birth.
FEV1 = Forced Expiratory Volume in 1 second.
NO = Nitric Oxide.
BDR = Bronchodilator response.
SPT = Skin Prick Test.
For abbreviations concerning questionnaires: see Table 2.
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is administered via a metered dose inhaler using a
volumatic spacer (GSK, Uxbridge, UK). Airway revers-
ibility is defined as an increase of FEV1 of ≥ 12% of
the predicted value 10 minutes after administration of
salbutamol.
Bronchial hyper responsiveness (BHR) is assessed by a
challenge with nebulized methacholine according to the
ERS/ATS guidelines [35]. All children will be asked to
withhold from taking rescue medication for at least
12 hours, and long acting beta two agonists at least
24 hours beforehand. A child will be defined as having
BHR when FEV1 has dropped by ≥20% from baselineduring the inhalation challenge. In children with a base-
line FEV1 ≤70% no challenge will be performed.
In all known patients with asthma spirometry assess-
ment (a bronchodilator response (BDR) or on indication
a challenge test) is annually performed, according to the
national guideline [33].
Other test results
Depending on the situation of the patient, more diagnostic
tests may be performed when this is considered necessary
for patient care by the physician. For instance, in a child
presenting with recurrent infections initially a culture may
be taken and lab tests to assess the immunologic status
Figure 2 Structure and way of usage of the Electronic Portal. * = Patient consulting one of the EN members, A = Asthma, RTI = Respiratory
Tract Infections, AR = Allergic Rhinoconjunctivitis, E = Eczema, FA = Food Allergy, ··· To be developed.
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the diagnosis of asthma. The EP does offer the opportunity
to enter those test results in the system in a structured way.
Cultures (nasopharyngeal, sputum, ear, nose) and lab
results in case of suspicion of a immune deficiency can be
registered when applicable. Atopic test results, such as an
ImmunoCAP for food allergens or inhalation allergens,
food challenge results or skin prick test results can be
entered. Test results can be filled in on predefined sche-
dules. Also the doctors-diagnosis will be entered in the EP,
and other diagnoses can be entered over time.
Follow up and study endpoints
By activating the follow up function in the EP, patients
are notified by email that a short questionnaire is ready
to be filled in by parents and/or patient in the EP at pre-
defined 3-month intervals, which is once every season.
(content: see Table 1 section follow-up). In order to ob-
tain a validated measure of asthma control, the EP uses
the validated C-ACT, or ACT, depending on the age of
the child. Adherence to treatment is assessed by using
the Medication Adherence Report Scale (MARS) com-
prising questions on medication use behavior and adher-
ence [36]. Medication use is registered by parents.
Privacy
The handling of personal data complies with the Dutch
Personal Data Protection Act. All data are stored in a
large database, which is maintained by Vital Health Soft-
ware. Storage and protection of the data is performed
according to the NEN 7510 guideline. Privacy is pro-
tected by encrypted storage of personal information in
the database. Exchange of data is protected by a security
protocol to prevent damage, loss, unauthorized access or
abuse of data. The EP can only be accessed with per-
sonal access codes.
The EP offers different user levels. Each level has its
own function and privileges, such as a professional (togive access to the EP to patients, and to view their own
recruited data), an application manager (to give access
to the EP to professionals; access to all processes and
modules, including the databases), and patient (access to
their own data). Each participating centre has its own




At the time of writing 1500 children have been invited to
participate, of whom the baseline questionnaire has been
completed in 740 (49%) patients. 478 patients were
selected to be followed up based on a diagnosis of a recent
asthma diagnosis or new symptoms that were assigned to
asthma by the pediatrician. Recruitment has been under-
way for 1 year in 3 centers (Figure 2), for 5 months in 2
centers and 2 months in one center. Two other centers
have confirmed participation in the study, and will start at
the end of 2012 with inclusion.
Discussion
In current clinical practice large amounts of data are
gathered during routine patient care. Very little of these
data are available for research purposes because data are
not recorded in a structured way. Here we describe an
EP which facilitates the EN to collect data in a struc-
tured way with minimal effort of the caregivers them-
selves. This EP offers several opportunities.
Since the start of inclusion, in June 2011, 1500 patients
were invited to participate. At present 740 patients (49%)
have completed the baseline questionnaire. Most patients
that have not completed the questionnaire are known
asthmatic patients that visit their doctor once per year.
These patients will fill in the questionnaire shortly before
their next doctor visit. In 95% of the cases informed con-
sent was given to use EP-data for research purposes. This
shows the EN is able to gather a large number of patients
Table 2 Questionnaires in the additional part of the Electronic Portal
Questionnaire Description Score range
RAND GHRI
[14,15]
7-item general health questionnaire. Developed for use in children 0,5-12 years
of age
Range: 7-32
32 = good health
C-ACT [16] 7-item questionnaire. Developed to measure asthma control in children 4–
11 years of age. 4 questions are for the child, 3 for the parent.
Range: 0-27
≥ 20 = well controlled
ACT [17] 5-item questionnaire developed to measure asthma control in children ≥12
years.
Range: 5-25
≥ 20 = well controlled
MARS [18] 9-item questionnaire, developed to measure medication adherence. Range 0-5
Mean score >4.5 = ‘adherent’
PAQLQ [19] 23-item questionnaire, in 3 domains. Developed to measure asthma-specific
health-related QoL in children 6–18 years of age.
Range 0-7
higher scores indicate better QoL
Brouilette
score [20]
3-item questionnaire to assess presence of OSAS > 3,5: OSAS present
- 1 to 3.5: uncertain OSAS
< −1: OSAS not present
OM6 [21] 6-item questionnaire in 6 domains. Developed to measure change in ear-related




ARIA [22] 5-item questionnaire, developed to measure presence and severity of rhino-
conjunctivitis
Classification into: intermittent or persistent
rhinitis; and severity: mild or moderate/severe
PRQLQ [23] 23-item questionnaire in 5 domains. Developed to measure the functional
problems in rhino-conjunctivitis in children 6–12 years of age
Range: 0–6 (mean)
6 = maximal impairment in health related quality
of life
AdolRQLQ [24] 25-item questionnaire in 6 domains. Developed to measure the functional
problems in rhino-conjunctivitis in children 12–17 years of age
Range: 0–6 (mean)
6 = maximal impairment in health related quality
of life
FAQLQ-CF [25] 24-item questionnaire, in 4 domains. Developed to measure food allergy related
QoL in children 8–12 years of age
Range: 1–7 (mean score)
7 = maximal impairment in health related quality
of life
FAQLQ-TF[26] 23-item questionnaire, in 3 domains. Developed to measure food allergy related
QoL in children 13–17 years of age
Range: 1–7 (mean score)
7 = maximal impairment in health related quality
of life
SA-EASI [27,28] 10-item questionnaire. Developed to measure the caregiver's self-assessment of
the severity of his/her child's atopic dermatitis
Range: 0–72 (acute score)
72 = very severe
IDQL [29] 10-item questionnaire. Developed to measure < 4 years of age Range: 0-30
higher score means larger impairment of QoL
CDLQI [30] 10-item questionnaire. Developed to measure 4–16 years of age Range: 0-30
higher score means larger impairment of QoL
RAND GHRI, RAND General health rating index.
C-ACT, Child-Asthma Control Test.
ACT, Asthma Control Test.
MARS-9, 9-item Medicine Adherence Rating Scale.
PAQLQ, Paediatric Asthma Quality of Life Questionnaire.
OM6, 6-item Otitis Media questionnaire.
ARIA, Allergic Rhinitis and its Impact on Asthma.
OSAS; Obstructive Sleep Apnoea Syndrome.
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will be available within a relatively short time.
Large population based observational studies, mainly
birth cohort studies, have been published and mainly
studied determinants of asthma [37-39]. These data are
not suitable to study treatment related asthma phenotypes
of asthma in children (e.g. treatment response to inhaledsteroids in asthmatic patients with eczema, compared to
those without eczema; or treatment response to long-
acting beta-agonists in asthmatic patients with marked air-
way reversibility compared to those without (or with
minor) reversibility); firstly because of the small number
of patients with asthma in most of these studies. Although
birth cohorts may be large, asthma may be present in
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ber of patients using asthma medication on regular basis,
which is only a sample of this 5%, does not allow compar-
ing therapy response within the different treatment regi-
mens. Especially in a heterogeneous disease such as
asthma, large patient numbers are needed to explore those
treatment defining phenotypes.
Strict inclusion criteria are used in randomized trials
to study the efficacy of treatment trials. The outcomes of
those studies are applicable to this selected group, but
difficult to generalize in the heterogenic asthmatic popu-
lation seen in daily practice. The EP enables collection
of data gathered during daily practice of an unselected
population with asthma (and other atopic diseases), for
research purposes. By including large samples of
patients, the outcomes will be usable in daily practice.
Data from the EP will be used to study the effectiveness
instead of the efficacy, which makes the outcomes more
applicable in daily practice.
Currently, the automatic follow up function is enabled
for asthmatic patients only. However, this function will be
available at the end of this year for the other disease topics
included in the EP: allergic rhinoconjunctivitis, eczema,
food allergy and (upper and lower-) respiratory tract
infections.
Apart from the research relevance, the patients partici-
pating in the EP will be followed up in time, which
means that their complaints will be monitored actively
by the EP without extra effort from the doctor. In regu-
lar asthma care, the frequency of visits is often once per
year in stable periods. During this visit it may be difficult
for parents and patient to recall how the last 12 months
have been. The EP makes it possible to have a whole
year through-overview of asthma control, medical treat-
ment response and medication use for the doctor, as well
as for the patient. Transparency in hospital care is also
increased by access to their test results in the electronic
EP by each individual patient, which may increase the
involvement of the patient in his treatment [40].
The EP supports a more structured way of working
within the collaborative network. This may support the
use and implementation of national guidelines on atopic
diseases. Each participating hospital creates its own pa-
tient database. With this database the performance of each
centre can be monitored and compared to other centers.
Furthermore, working strategies or other knowledge can
be exchanged to improve daily practice within the centers.
Due to the use of a web based application, there will
be a selection in the population that is included in the
EP. Currently in the Netherlands, 1% of all persons be-
tween 11–45 years of age do not have access to internet
at home [41]. The main reason for not having internet-
access is ‘no interest’. Because financial reasons seem to
play a much smaller role, this will probably not lead to aselection in our patient group (in social economic state).
However, also a good understanding of, and ability to
read the Dutch language is an inclusion criterion. This
will lead to a selection of patients, because the 1.5 mil-
lion functional analphabetic persons in the Netherlands
will mainly evolve within the lower social economic
class. One third of those persons are foreigners [42].
How large this selection is will be analyzed.
We conclude that the use of current web-based
services like the described EP can be helpful to support
extensive data collection in Expert Networks.
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